Skip to Content
Merck
  • Factors influencing long-term regression after posterior chamber phakic intraocular lens implantation for moderate to high myopia.

Factors influencing long-term regression after posterior chamber phakic intraocular lens implantation for moderate to high myopia.

American journal of ophthalmology (2014-04-05)
Kazutaka Kamiya, Kimiya Shimizu, Akihito Igarashi, Hidenaga Kobashi
ABSTRACT

To evaluate the factors affecting the long-term regression after posterior chamber phakic intraocular lens (Visian ICL; STAAR Surgical) implantation for myopia. Retrospective observational case series. We retrospectively examined 60 eyes of 35 consecutive patients (age, 38.4 ± 9.3 years [mean ± standard deviation]) with myopic refractive errors of -4.00 to -15.25 diopters (D) undergoing ICL implantation. We assessed the amount of myopic regression from 1 month to 6 years after surgery. Stepwise multiple regression analysis was used to assess the factors affecting the amount of myopic regression. The mean myopic regression from 1 month to 6 years after surgery was -0.33 ± 0.71 D (0.75 to -3.00 D). Explanatory variables relevant to the myopic regression were, in order of influence, patient age (partial regression coefficient B = -0.042, P < .0001) and preoperative axial length (B = -0.186, P = .013) (adjusted R(2) = 0.300). No significant correlation was seen with other clinical factors such as sex, preoperative refraction, intraocular pressure, white-to-white distance, anterior chamber depth, central corneal thickness, or mean keratometric readings. Although the great majority of the variance remains unexplained, eyes of older patients and eyes with longer axial length are more predisposed to show greater myopic regression after ICL implantation. These results indicate that not only patient age but also axial length may play some role in predicting the long-term refractive outcomes of this surgical procedure.

MATERIALS
Product Number
Brand
Product Description

USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
Acetylcholine chloride, suitable for cell culture
Sigma-Aldrich
Tropicamide, solid
Sigma-Aldrich
Acetylcholine chloride, ≥99% (TLC)
Sigma-Aldrich
Acetylcholine chloride, pkg of 150 mg (per vial)
Supelco
Levofloxacin, analytical standard
Supelco
Betamethasone, VETRANAL®, analytical standard
Supelco
Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Betamethasone, European Pharmacopoeia (EP) Reference Standard
Acetylcholine chloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetylcholine chloride, ≥99% (TLC), free-flowing, Redi-Dri
Tropicamide, European Pharmacopoeia (EP) Reference Standard
USP
Acetylcholine chloride, United States Pharmacopeia (USP) Reference Standard
USP
Betamethasone, United States Pharmacopeia (USP) Reference Standard